Friday, July 29, 2016

Oramed posts positive oral insulin data

Oramed posts positive oral insulin data

July 28, 2016 by · Leave a Comment 

Tweet Oramed Pharmaceuticals (NASDAQ:ORMP) reported additional data from the recently concluded Phase 2b trial of its oral insulin capsule ORMD-0801 in adults with Type 2 diabetes. The data indicate a statistically significant lowering of glucose relative to placebo across several endpoints. “ORMD-0801 was safe and efficacious in reducing blood glucose endpoints with a promising clinically […]

Feltl upgrades Novadaq to strong buy

Feltl upgrades Novadaq to strong buy

July 28, 2016 by · Leave a Comment 

Tweet Feltl & Co. upgraded Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) to “strong buy” from “buy” after the company posted second quarter revenue ahead of expectations yesterday on the strength of its direct sales business. Analyst Ben Haynor maintained his price target of $15 on Novadaq. The stock was quoted $10.13, up $1.30, at mid-day Thursday. “At […]

Novadaq Q2 revenue climbs 34%

Novadaq Q2 revenue climbs 34%

July 27, 2016 by · Leave a Comment 

Tweet Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) reported revenue of $20.1-million in the second quarter, an increase of 34% from $15.1-million a year ago. Total direct sales in the latest quarter increased by $4.4-million, or 37%, and total partnered/international sales rose by $600,000, or 21%, compared with the same period last year. The company estimates that the number […]

Anavex reports Phase 2a efficacy data in AD

Anavex reports Phase 2a efficacy data in AD

July 27, 2016 by · Leave a Comment 

Tweet Anavex Life Sciences (NASDAQ:AVXL) announced efficacy data through 31 weeks from the ongoing ANAVEX 2-73 Phase 2a study in mild-to-moderate Alzheimer’s patients at the Alzheimer’s Association International Conference in Toronto. Overall, efficacy results demonstrate what appears to be a converging and consistent response for all quantitative endpoints through 31 weeks, including cognitive and functional […]

BTIG downgrades NeoGenomics to neutral

BTIG downgrades NeoGenomics to neutral

July 27, 2016 by · Leave a Comment 

Tweet BTIG Research downgraded NeoGenomics (NASDAQ:NEO) to “neutral” from “buy.” The stock closed at $9.05 on Tuesday. Analyst Dr. Sean Lavin writes that second quarter results were largely in-line. “The base business continues to trend well and with more clarity around Medicare in 2017, we think downside risk is fairly modest,” he said. “[NeoGenomics’] shares […]

Oramed names Dr. Roy Eldor as CMD

Oramed names Dr. Roy Eldor as CMD

July 26, 2016 by · Leave a Comment 

Tweet Oramed Pharmaceuticals (NASDAQ:ORMP) appointed Dr. Roy Eldor to the newly created post of chief medical director. “We are very pleased to welcome Dr. Eldor on board at this pivotal time for Oramed as we head towards a Phase 3 trial for our oral insulin capsule, ORMD-0801,” CEO, Nadav Kidron, said in a statement. Dr. […]

Tandem expands pediatric indication of insulin pump

Tandem expands pediatric indication of insulin pump

July 26, 2016 by · Leave a Comment 

Tweet Tandem Diabetes Care (NASDAQ:TNDM) received FDA clearance of an expanded pediatric indication for the t:slim Insulin Pump, lowering its use to children age 6 and older from children age 12 and older. The t:slim Pump is the first and only touchscreen insulin pump cleared by the FDA. The expanded pediatric indication applies to the […]

Viking reports positive POC study in X-ALD

Viking reports positive POC study in X-ALD

July 26, 2016 by · Leave a Comment 

Tweet Viking Therapeutics (NASDAQ:VKTX) announced positive top-line results from a proof-of-concept study of VK0214 in a mouse model of X-linked adrenoleukodystrophy (X-ALD). The results showed that VK0214 rapidly reduced very long chain fatty acid (VLCFA) levels in plasma by more than 25% in treated animals, compared with vehicle controls.  The study successfully achieved its primary […]

Ocular Therapeutix gets complete response letter

Ocular Therapeutix gets complete response letter

July 25, 2016 by · Leave a Comment 

Tweet Ocular Therapeutix (NASDAQ:OCUL) received a complete response letter (CRL) from the FDA about its NDA for DEXTENZA for intracanalicular use in the treatment of ocular pain occurring after ophthalmic surgery. Concerns raised by the FDA pertain to deficiencies in manufacturing process and controls identified during a pre-NDA approval inspection of the company’s manufacturing facility. […]

Anavex presents safety data in AD

Anavex presents safety data in AD

July 25, 2016 by · Leave a Comment 

Tweet Anavex Life Sciences (NASDAQ:AVXL) presented safety data for its ANAVEX 2-73 drug candidate at the Alzheimer’s Association International Conference 2016 in Toronto. Data presented in a poster highlights the evaluation of a maximum tolerated dose of ANAVEX 2-73 as primary endpoint of the Phase 2a study in mild-to-moderate Alzheimer’s patients, as well as additional […]

Next Page »

Email Newsletters with Constant Contact
Google+